Preterm Birth Diagnostic Test Kits Market Analysis

Preterm Birth Diagnostic Test Kits Market Analysis

Based on product type, the preterm birth diagnostic test kits market is segmented into fetal fibronectin test kits (fFN), placental alpha micro-globulin-1 test kits (PAMG-1), insulin like growth factor binding protein-1 test kits (IGFBP-1), and others. The fetal fibronectin test kits (fFN) segment held the largest revenue size over USD 197 million in 2022 and is estimated to witness significant growth more than USD 409 million by 2032. The fFN test demonstrates high sensitivity in detecting the presence of fetal fibronectin, a protein that acts as a biomarker for preterm birth. It can accurately identify women at higher risk of delivering prematurely. Furthermore, an increase in the availability of product type coupled with several other businesses working towards creating innovative technology will support the segment's revenue growth in the coming years.
 

Preterm birth diagnostic test kits market is bifurcated based on the sample type including blood sample, urine sample, and vaginal discharge sample. The blood sample segment dominated the market and is anticipated to grow over USD 347 million by 2032. Blood-based tests have demonstrated high diagnostic accuracy in identifying biomarkers and indicators associated with preterm birth. These tests can measure specific proteins, hormones, or genetic markers present in the maternal blood that may be indicative of an increased risk of preterm birth. Thus, the aforementioned factors will drive the segmental growth.
 

The industry is segmented by end-use into hospitals, diagnostic centers, clinics, and others. Diagnostic centers segment dominated the global preterm birth diagnostic test kits market accounting for more than 43% market share in 2022 and is estimated to witness significant revenue over USD 370 million by 2032. The diagnostic centers segment is anticipated to hold high growth potential during the analysis period. Factors such as surging laboratory tests and rising preference towards diagnostics laboratories due to presence of advanced technologies and cost-effective treatment will fuel market growth. Additionally, these centers provide early and accurate disease diagnosis and patient management, thus, anticipated to augment the segmental growth in upcoming years.
 

U.S. preterm birth diagnostic test kits industry accounted for more than USD 158 million in 2022 and will grow momentously more than USD 344 million by 2032. The affordability of preterm birth diagnostic test kits among the target population base and ongoing technological developments are primarily responsible for the growth of the regional preterm birth diagnostic test kits industry. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America preterm birth diagnostic test kits market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S. hence, the potential for market expansion will stimulate over the coming years.